193 related articles for article (PubMed ID: 31188728)
1. Prostate Transition Zone Fibrosis is Associated with Clinical Progression in the MTOPS Study.
Macoska JA; Uchtmann KS; Leverson GE; McVary KT; Ricke WA
J Urol; 2019 Dec; 202(6):1240-1247. PubMed ID: 31188728
[TBL] [Abstract][Full Text] [Related]
2. Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy.
Fwu CW; Eggers PW; Kirkali Z; McVary KT; Burrows PK; Kusek JW
J Urol; 2014 Jun; 191(6):1828-34. PubMed ID: 24342143
[TBL] [Abstract][Full Text] [Related]
3. Three-Year Treatment Outcomes of Water Vapor Thermal Therapy Compared to Doxazosin, Finasteride and Combination Drug Therapy in Men with Benign Prostatic Hyperplasia: Cohort Data from the MTOPS Trial.
Gupta N; Rogers T; Holland B; Helo S; Dynda D; McVary KT
J Urol; 2018 Aug; 200(2):405-413. PubMed ID: 29499208
[TBL] [Abstract][Full Text] [Related]
4. Is Sexual Function Better Preserved After Water Vapor Thermal Therapy or Medical Therapy for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia?
McVary KT; Rogers T; Mahon J; Gupta NK
J Sex Med; 2018 Dec; 15(12):1728-1738. PubMed ID: 30446471
[TBL] [Abstract][Full Text] [Related]
5. Time Course of Incident Adverse Experiences Associated with Doxazosin, Finasteride and Combination Therapy in Men with Benign Prostatic Hyperplasia: The MTOPS Trial.
Kaplan SA; Lee JY; Meehan AG; Kusek JW
J Urol; 2016 Jun; 195(6):1825-9. PubMed ID: 26678956
[TBL] [Abstract][Full Text] [Related]
6. Long-term effects of doxazosin, finasteride and combination therapy on quality of life in men with benign prostatic hyperplasia.
Fwu CW; Eggers PW; Kaplan SA; Kirkali Z; Lee JY; Kusek JW
J Urol; 2013 Jul; 190(1):187-93. PubMed ID: 23357210
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate: data from the MTOPS trial.
Kaplan SA; Lee JY; Meehan AG; Kusek JW;
J Urol; 2011 Apr; 185(4):1369-73. PubMed ID: 21334655
[TBL] [Abstract][Full Text] [Related]
8. Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial.
Kaplan SA; Roehrborn CG; McConnell JD; Meehan AG; Surynawanshi S; Lee JY; Rotonda J; Kusek JW; Nyberg LM;
J Urol; 2008 Sep; 180(3):1030-2; discussion 1032-3. PubMed ID: 18639298
[TBL] [Abstract][Full Text] [Related]
9. Finasteride for benign prostatic hyperplasia.
Tacklind J; Fink HA; Macdonald R; Rutks I; Wilt TJ
Cochrane Database Syst Rev; 2010 Oct; 2010(10):CD006015. PubMed ID: 20927745
[TBL] [Abstract][Full Text] [Related]
10. Ultrasound image features of intravesical prostatic protrusion indicated failure of medication therapy of finasteride and doxazosin in patients with benign prostatic hyperplasia (LUTS/BPH).
Liu Q; Zhu Y; Liu J; Qi J; Kang J
Int Urol Nephrol; 2017 Mar; 49(3):399-404. PubMed ID: 27987130
[TBL] [Abstract][Full Text] [Related]
11. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.
Logan YT; Belgeri MT
Am J Geriatr Pharmacother; 2005 Jun; 3(2):103-14. PubMed ID: 16129387
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Combination Therapy Versus Monotherapy in Benign Prostatic Hyperplasia: A Colombian Experience.
Guevara-Cuellar CA; Parody-Rúa E; Garcia-Perdomo HA; Arenas-Duque A
Value Health Reg Issues; 2018 Dec; 17():174-182. PubMed ID: 30415110
[TBL] [Abstract][Full Text] [Related]
13. The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.
Jin R; Strand DW; Forbes CM; Case T; Cates JMM; Liu Q; Ramirez-Solano M; Milne GL; Sanchez S; Wang ZY; Bjorling DE; Miller NL; Matusik RJ
Prostate; 2021 Sep; 81(13):944-955. PubMed ID: 34288015
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater.
Kaplan SA; McConnell JD; Roehrborn CG; Meehan AG; Lee MW; Noble WR; Kusek JW; Nyberg LM;
J Urol; 2006 Jan; 175(1):217-20; discussion 220-1. PubMed ID: 16406915
[TBL] [Abstract][Full Text] [Related]
15. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
McConnell JD; Roehrborn CG; Bautista OM; Andriole GL; Dixon CM; Kusek JW; Lepor H; McVary KT; Nyberg LM; Clarke HS; Crawford ED; Diokno A; Foley JP; Foster HE; Jacobs SC; Kaplan SA; Kreder KJ; Lieber MM; Lucia MS; Miller GJ; Menon M; Milam DF; Ramsdell JW; Schenkman NS; Slawin KM; Smith JA;
N Engl J Med; 2003 Dec; 349(25):2387-98. PubMed ID: 14681504
[TBL] [Abstract][Full Text] [Related]
16. Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
Jhang JF; Jiang YH; Kuo HC
Int J Clin Pract; 2013 Dec; 67(12):1327-33. PubMed ID: 24246211
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial.
Kirby RS; Roehrborn C; Boyle P; Bartsch G; Jardin A; Cary MM; Sweeney M; Grossman EB;
Urology; 2003 Jan; 61(1):119-26. PubMed ID: 12559281
[TBL] [Abstract][Full Text] [Related]
18. The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia.
Johnson TM; Burrows PK; Kusek JW; Nyberg LM; Tenover JL; Lepor H; Roehrborn CG;
J Urol; 2007 Nov; 178(5):2045-50; discussion 2050-1. PubMed ID: 17869295
[TBL] [Abstract][Full Text] [Related]
19. Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects.
MacDonald R; Wilt TJ; Howe RW
BJU Int; 2004 Dec; 94(9):1263-70. PubMed ID: 15610102
[TBL] [Abstract][Full Text] [Related]
20. Assessment of Frailty and Association With Progression of Benign Prostatic Hyperplasia Symptoms and Serious Adverse Events Among Men Using Drug Therapy.
Bauer SR; Walter LC; Ensrud KE; Suskind AM; Newman JC; Ricke WA; Liu TT; McVary KT; Covinsky K
JAMA Netw Open; 2021 Nov; 4(11):e2134427. PubMed ID: 34817584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
